HealthEconomics.Com

Health Outcomes, Market Access, and HEOR Global News Resources and Jobs.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
    • Career Fair
    • Order the 2017 HEOR and Market Access Global Salary Survey
  • Business Directory
  • Industry Events
    • Webinar Services from HealthEconomics.Com
    • View Conferences
    • View Webinars
    • View Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • 2017 Salary Survey
    • Free Marketing Consultation!
    • Be a Better Writer
    • Effective eMail Marketing. New for 2017!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Education Resources
    • White Papers
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute
  • Salary Survey
You are here: Home / Featured / New Syndicated Report – Orphan Drug Launch Strategies: Case Studies

New Syndicated Report – Orphan Drug Launch Strategies: Case Studies

Compared to mainstream drug launches, it’s usually a much smaller team with fewer resources that are tasked with bringing a new orphan drug to market. And the market itself is smaller too – fewer specialists to talk to, fewer physicians to educate, and fewer patients to engage with.

But smaller doesn’t mean less important.

Every activity is so much more visible, which makes the pressure to get it right first time even more intense than usual. And the higher price tag associated with rare disease treatments means that the commercial risks and the potential benefits are far from small either. Launching an orphan drug is clearly not for the faint-hearted.

This report will enable you to:

  • Compare the experiences of 8 pharma companies who have successfully launched at least one orphan drug, including Celgene, GlaxoSmithKline, Roche, Boehringer Ingelheim and Pfizer.
  • Understand which factors should be considered when setting orphan drug prices and find out about the specific pricing strategies adopted for each case study drug.
  • Assess the stakeholder engagement strategies needed to address the barriers to success that exist for rare disease therapies.

Click here for more information and purchasing details.



You might also be interested in:

  • Study Reveals Doctors Tight-Lipped on Cancer Costs May 20, 2017
  • Syndicated Reports Spotlight RA, Type 2 Diabetes Mellitus January 15, 2018
  • Celgene Delivers 9% Price Hike on Revlimid, Pomalyst October 28, 2017
  • The ROI of Orphan Drugs: Ensuring Optimal Returns December 12, 2017
  • Investors Blast Pfizer’s New Round of Price Hikes June 15, 2017
  • KAM Metrics: Driving Efficiency, Measuring Success April 5, 2018
  • Celgene’s Jessica Leygues Talks Patient Engagement March 26, 2018

 

View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Conference of the Week:

Link of the Week:

Job of the Week:

Webinar of the Week:

Syndicated Reports

Biosimilars: US Payer Perspectives

KAM Metrics: Driving Efficiency, Measuring Success

Biosimilars: E.U. Payer Perspectives

MSL Teams: Field Force Size and Structure

Market Access Impact: Type 2 Diabetes Mellitus (Injectables) (US) 2017

HealthEconomics.Com

HealthEconomics.Com

  • News
  • Conferences
  • Resources
  • Reports
  • Jobs
  • Consulting
  • Newsletters
  • White Papers

More Links

  • Jobs
  • Education
  • Graduate Schools
  • Webinar Services

Support & Contact

  • Contact Us

About

  • About Us
  • Advertise
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HE Institute

Strategy, Training, Education, and Communications in HEOR & Market Access.

HE Business Directory

Online directory of HEOR, pricing, reimbursement, and market access service providers.

tHEORetically Speaking Blog

Insights and observations for HEOR, market access, pricing, reimbursement, and health policy.

HE Online Career Fairs

Connecting employers and job seekers in an engaging, interactive way for HEOR and market access.

HE Webinars

Online educational and informational seminars for HEOR, market access, pricing, and reimbursement.
  • HealthEconomics.Com
  • About HealthEconomics.Com
  • Advertising Inquiries
  • Careers
  • Contact

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
    • Career Fair
    • Order the 2017 HEOR and Market Access Global Salary Survey
  • Business Directory
  • Industry Events
    • Webinar Services from HealthEconomics.Com
    • View Conferences
    • View Webinars
    • View Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • 2017 Salary Survey
    • Free Marketing Consultation!
    • Be a Better Writer
    • Effective eMail Marketing. New for 2017!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Education Resources
    • White Papers
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute
  • Salary Survey